Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 276

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 276
---
 board of directors and committees of our board of directors from and after the completion of this offering: Cash Compensation. Under this policy, we will pay each of our non-employee directors cash retainers for service on our board of directors and committees of our board of directors as follows:

|                                                                                        |     | Annual   
 Cash     
 Retainer 
 ($)      |        |
| Annual retainer                                                                        |     |          | 40,000 |
| Additional retainer for non-executive chair                                            |     |          | 30,000 |
| Additional retainer for audit committee chair                                          |     |          | 20,000 |
| Additional retainer for audit committee non-chair member                               |     |          | 10,000 |
| Additional retainer for compensation committee chair                                   |     |          | 12,000 |
| Additional retainer for compensation committee non-chair member                        |     |          |  6,000 |
| Additional retainer for nominating and corporate governance committee chair            |     |          | 10,000 |
| Additional retainer for nominating and corporate governance committee non-chair member |     |          |  5,000 |

We will also reimburse each non-employee director for ordinary, necessary and reasonable out-of-pocket travel expenses actually incurred by such director in connection with in-person attendance at and participation in meetings of our board of directors and committees of our board of directors. Equity Compensation. In addition to cash compensation, each non-employee director will be eligible to receive options under our 2025 Plan. All options granted under the policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the fair market value of the underlying common stock on the date of grant, and a term of ten years from the date of grant, subject to earlier termination in connection with a termination of service. Vesting schedules for equity awards will be subject to the non-employee director’s continuous service with us on each applicable vesting date, provided that each option will vest in full upon a change in control (as defined in the 2025 Plan). Initial Award.Each new non-employee director elected or appointed to our board of directors after the effective date of the policy will automatically be granted an initial, one-time stock option award for 20,000 shares. The initial option grant will vest in substantially equal annual installments over a three-year period such that the option is fully vested on the third anniversary of the grant date. Annual Awards.On the date of each annual